Evidence map›Paper›PMID 38178209›Full record

ArticleImplementation science communications2024

A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial.

Masaki Fujiwara, Yuto Yamada, Tsuyoshi Etoh, Taichi Shimazu, Masafumi Kodama, Norihito Yamada, Takahiro Asada, Shigeo Horii, Takafumi Kobayashi, Teruo Hayashi and 10 more

Abstract read
In one paragraph

Article in Implementation science communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Masaki FujiwaraDepartment of Neuropsychiatry, Okayama University Hospital, Okayama, Japan.
Yuto YamadaDepartment of Neuropsychiatry, Okayama University Hospital, Okayama, Japan.
Tsuyoshi EtohDepartment of Nursing, Shimane University Hospital, Izumo, Japan.
Taichi ShimazuDivision of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Masafumi KodamaOkayama Psychiatric Medical Center, Okayama, Japan.
Norihito YamadaOkayama Psychiatric Medical Center, Okayama, Japan.
Takahiro AsadaZikei Hospital, Okayama, Japan.
Shigeo HoriiZikei Hospital, Okayama, Japan.
Takafumi KobayashiShimane Prefectural Psychiatric Medical Center, Izumo, Japan.
Teruo HayashiSeiwakai Nishikawa Hospital, Hamada, Japan.
Yoshitaka EharaSekizen Hospital, Tsuyama, Japan.
Kenji FukudaKonan Hospital, Matsue, Japan.
Keita HaradaDepartment of Gastroenterology, Okayama Saiseikai General Hospital, Okayama, Japan.
Maiko FujimoriDivision of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Miyuki OdawaraDivision of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Hirokazu TakahashiDivision of Screening Assessment and Management, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Shiro HinotsuDepartment of Biostatistics and Data Management, Sapporo Medical University, Sapporo, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yosuke UchitomiDivision of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Masatoshi InagakiDepartment of Psychiatry, Faculty of Medicine, Shimane University, Izumo, Shimane, 693-8501, Japan. minagaki@med.shimane-u.ac.jp.ORCID http://orcid.org/0000-0002-9822-8649

Funding

Ministry of Health, Labour and Welfare 21EA1013Ministry of Health, Labour and Welfare 23EA1031
6 · The paper itself

Abstract

backgroundPeople with schizophrenia have a lower colorectal screening rate than the general population. A previous study reported an intervention using case management to encourage colorectal cancer screening for patients with schizophrenia in psychiatric outpatient settings. In this feasibility study, we developed provider-level implementation strategies and evaluated the feasibility of conducting a definitive trial in terms of the penetration of the intervention assessed at the patient level. Additionally, we examined the fidelity of strategies to implement the intervention at the provider level in a routine clinical psychiatric setting.

methodsThis was a multicenter, single-arm feasibility study with medical staff at psychiatric hospitals in Japan. The provider-level implementation strategies developed in this study included three key elements (organizing an implementation team appointed by the facility director, interactive assistance using a clear guide that outlines who in the hospital should do what, and developing accessible educational materials) to overcome major barriers to implementation of the intervention and four additional elements (progress monitoring, joint meetings and information sharing among participating sites, adaptation of encouragement methods to specific contexts, and education of on-site staff), with reference to the elements identified in the Expert Recommendations for Implementing Change (ERIC). The feasibility of the strategies was evaluated by the proportion of patients who were eligible for encouragement (patients with schizophrenia aged 40, 50, or 60) who received encouragement. We set the goal of providing encouragement to at least 40% of eligible patients at each site.

resultsTwo public and four private psychiatric hospitals in Okayama and Shimane prefectures participated in this study. Regarding fidelity, all elements of the strategies were conducted as planned. Following the procedures in the guide, each team prepared and provided encouragement according to their own facility and region. Penetration, defined as the proportion of eligible patients who received encouragement, ranged from 33.3 to 100%; five of the six facilities achieved the target proportion.

conclusionsThe provider-level implementation strategies to implement encouragement were feasible in terms of penetration of the intervention assessed at the patient level. The results support the feasibility of proceeding with a future definitive trial of these strategies.

trial registrationjRCT, jRCT1060220026 . Registered on 06/04/2022.

Indexed as

Cancer screeningCase managementImplementationProvider levelSchizophrenia

Identifiers

PMID38178209
PMCPMC10768128

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.